Reflections, Reconciliation & Repsychopathologization | Beyond Gender 2025 Year in Review
1 January 2026
Global
The three Beyond Gender hosts take stock of a turbulent 2025 — from Trump's executive orders and the HHS report to the For Women Scotland ruling and the UK's puberty blockers trial. For European listeners, the year looked different: several Nordic countries had already moved to restrict paediatric gender medicine, and the continent watched Anglo-American institutions begin to catch up. The hosts' central concept — repsychopathologization, returning psychological understanding to gender distress — resonates with clinicians across Sweden, the Netherlands, France, and Germany who have been asking the same questions for years.
When three of the clearest voices in the gender-medicine debate sit down to review a year as consequential as 2025, the result is less a highlight reel than a reckoning. Stella O'Malley, Mia Hughes, and Dr. Bret Alderman spend this New Year's Day episode mapping what shifted, what stalled, and what the landscape now demands — and for listeners across Europe, much of what they describe carries an unmistakable echo. The episode moves through a sequence of landmark events. Donald Trump's executive orders early in 2025 sent shockwaves far beyond American borders, prompting European governments and health authorities to reassess their alignment with American clinical frameworks. The HHS report on gender medicine then added empirical weight to a debate long dismissed as politically motivated. The For Women Scotland ruling clarified the legal meaning of sex in ways that reverberate across jurisdictions, and the UK puberty blockers trial — the formal legal testing of restrictions that followed Britain's national clinical review — marked a turning point that European paediatric clinicians have been watching with close attention. Against these signals of change, the hosts examine Canada as a cautionary study in institutional inertia. Where several Nordic countries, and increasingly other European nations, moved to restrict or pause paediatric gender medicine on precautionary grounds, Canada instead doubled down — a pattern the hosts find both baffling and instructive. For European health policymakers, Canada's trajectory offers a warning about the costs of allowing ideological momentum to substitute for evidence. The episode's most intellectually striking contribution is the concept its title foregrounds: repsychopathologization. The word is deliberate. It does not carry a stigmatising meaning; it signals the restoration of psychological understanding — careful, humane, evidence-grounded clinical thinking — to a domain that was abruptly stripped of it when affirmative-only protocols took hold. For psychotherapists and psychiatrists in Sweden, the Netherlands, France, and Germany who have watched colleagues silenced or sidelined for raising exactly these questions, the framing offers both a vocabulary and a legitimacy that the clinical conversation has badly needed. What 2025 ultimately demonstrated, in the hosts' reading, is that the evidence-based position is no longer a fringe one. Institutions that once seemed immovable have shifted; reports that once seemed unthinkable have been published; rulings that once seemed impossible have come through. The hosts are clear-eyed, however, about what remains broken — not least the welfare of the young people caught inside systems that are still, in many countries, struggling to catch up. For European listeners, this episode serves as both an orientation and a provocation. The Nordic countries moved early; the UK is moving now; EU institutions and the larger continental health systems have yet to act with comparable urgency. 2026, the hosts suggest, will be the year that urgency is either seized or squandered — and the conversation they have been building across this past year gives that choice a shape and a weight it would not otherwise have.
